Mark T. Osterman, MD MSCE is an Associate Professor of Medicine at the University of Pennsylvania Perelman School of Medicine where he serves as the Associate Director of IBD Research for the Penn Inflammatory Bowel Disease Center. 

He has been heavily involved in clinical research in inflammatory bowel disease for the last 15 years, with a focus on clinical trials of novel therapies, optimization and safety of medical therapies using observational studies, therapeutic drug monitoring of immunosuppressant medications, prediction of response to biologic medications, and mucosal healing.  He has been lead PI or a steering committee member of a number of multi-center clinical trials. 

He is one of the nation’s pioneers of the study and use of proactive therapeutic drug monitoring for biologic therapy in IBD.  His work has been funded by the AGA, NIH, CCFA, pharmaceutical industries, and private philanthropy.  Dr. Osterman has recently served as Chair of the Chapter Medical Advisory Committee for the CCFA Philadelphia Chapter, for which he is also a board member.